Top

Internal and Emergency Medicine

Published in:

01-01-2022 | Petechiae | CE - LETTER TO THE EDITOR

Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?

Authors: Federico Pasin, Alberto Calabrese, Laura Pelagatti

Published in: Internal and Emergency Medicine | Issue 1/2022

Excerpt

Dear Editor, …

Tarawneh OH, Tarawneh HS (2021) Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol. https://doi.org/10.1002/ajh.26106CrossRefPubMedPubMedCentral

Helms JM, Ansteatt KT, Roberts JC, Kamatam S, Foong KS, Labayog JS, Tarantino MD (2021) Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine. J Blood Med 6(12):221–224CrossRef

Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, Bussel JB (2021) Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 96(5):534–537. https://doi.org/10.1002/ajh.26132 (Epub 2021 Mar 9)CrossRefPubMed

Perricone C, Ceccarelli F, Nesher G et al (2014) Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res 60:226–235CrossRef

Rinaldi M, Perricone C, Ortega-Hernandez OD et al (2014) Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines. Lupus 23:554–567CrossRef

Title: Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?
Authors: Federico Pasin
Alberto Calabrese
Laura Pelagatti
Publication date: 01-01-2022
Publisher: Springer International Publishing
Keywords: Petechiae
Vaccination
SARS-CoV-2
Thrombocytopenia
COVID-19
Published in: Internal and Emergency Medicine / Issue 1/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-021-02778-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Predictors of drug prescription in nursing home residents: results from the INCUR study

Incidence and outcome of delirium during helmet CPAP treatment in COVID-19 patients

The dual relationship between polypharmacy and frailty in nursing home residents: polypharmacy as a cause or a consequence?

Adult emergency department visits during the COVID-19 pandemic in Veneto region, Italy: a time-trend Analysis

A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin–tazobactam versus vancomycin cefepime

An unusual manifestation of a foreign body airway in a toddler

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page